Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts: Efficacy and Selection of Companion Imaging Counterpart.
ADAPT
DM1
HER2
albumin binding domain
cancer therapy
engineered scaffold protein
human epidermal growth factor receptor 2
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
02 Aug 2022
02 Aug 2022
Historique:
received:
04
07
2022
revised:
28
07
2022
accepted:
29
07
2022
entrez:
26
8
2022
pubmed:
27
8
2022
medline:
27
8
2022
Statut:
epublish
Résumé
Overexpression of the human epidermal growth factor receptor 2 (HER2) in breast and gastric cancer is exploited for targeted therapy using monoclonal antibodies and antibody-drug conjugates. Small engineered scaffold proteins, such as the albumin binding domain (ABD) derived affinity proteins (ADAPTs), are a promising new format of targeting probes for development of drug conjugates with well-defined structure and tunable pharmacokinetics. Radiolabeled ADAPT6 has shown excellent tumor-targeting properties in clinical trials. Recently, we developed a drug conjugate based on the HER2-targeting ADAPT6 fused to an albumin binding domain (ABD) for increased bioavailability and conjugated to DM1 for cytotoxic action, designated as ADAPT6-ABD-mcDM1. In this study, we investigated the therapeutic efficacy of this conjugate in mice bearing HER2-expressing SKOV3 ovarian cancer xenografts. A secondary aim was to evaluate several formats of imaging probes for visualization of HER2 expression in tumors. Administration of ADAPT6-ABD-mcDM1 provided a significant delay of tumor growth and increased the median survival of the mice, in comparison with both a non-targeting homologous construct (ADAPT
Identifiants
pubmed: 36015242
pii: pharmaceutics14081612
doi: 10.3390/pharmaceutics14081612
pmc: PMC9415843
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : VINNOVA
ID : 2019/00104
Organisme : Swedish Cancer Society
ID : CAN 21 1861 Pj
Organisme : Swedish Cancer Society
ID : 2020/181
Organisme : Swedish Cancer Society
ID : 20 0893 Pj
Références
Structure. 2013 Nov 5;21(11):1979-91
pubmed: 24095059
Pharmaceutics. 2021 Nov 21;13(11):
pubmed: 34834389
Int J Oncol. 2019 Jul;55(1):309-319
pubmed: 31180549
Pharmaceutics. 2021 Nov 03;13(11):
pubmed: 34834262
Oncol Rep. 2022 May;47(5):
pubmed: 35315504
J Control Release. 2016 Jul 10;233:48-56
pubmed: 27178808
Expert Opin Drug Deliv. 2016;13(3):401-19
pubmed: 26654403
Pharmaceutics. 2021 Mar 23;13(3):
pubmed: 33806887
N Engl J Med. 2008 Oct 23;359(17):1834-6
pubmed: 18946069
Cancer Treat Rev. 2012 May;38(3):212-7
pubmed: 21726959
Cancers (Basel). 2021 Aug 04;13(16):
pubmed: 34439094
Curr Opin Chem Biol. 2009 Jun;13(3):245-55
pubmed: 19501012
Pharmaceutics. 2022 Feb 26;14(3):
pubmed: 35335898
BioDrugs. 2018 Jun;32(3):233-243
pubmed: 29748739
Protein Eng Des Sel. 2018 May 1;31(5):159-171
pubmed: 30247737
N Engl J Med. 2008 Oct 23;359(17):1757-65
pubmed: 18946061
PLoS One. 2014 Aug 04;9(8):e103094
pubmed: 25089830
Int J Mol Sci. 2019 May 15;20(10):
pubmed: 31096563
Bioconjug Chem. 2014 Apr 16;25(4):656-64
pubmed: 24559399
Cancer Res. 2015 Oct 15;75(20):4364-71
pubmed: 26297736
Lancet Oncol. 2020 Jun;21(6):821-831
pubmed: 32437664
Signal Transduct Target Ther. 2022 Mar 22;7(1):93
pubmed: 35318309
Int J Mol Sci. 2021 Mar 09;22(5):
pubmed: 33803361
J Control Release. 2018 Oct 28;288:84-95
pubmed: 30172673
Int J Mol Sci. 2022 Feb 23;23(5):
pubmed: 35269611
Clin Cancer Res. 2009 Dec 1;15(23):7381-8
pubmed: 19920100
Br J Cancer. 2020 Mar;122(5):603-612
pubmed: 31839676
MAbs. 2014 Jan-Feb;6(1):34-45
pubmed: 24423619
J Nucl Med. 2021 Apr;62(4):493-499
pubmed: 32817142
Annu Rev Pharmacol Toxicol. 2015;55:489-511
pubmed: 25562645
J Nucl Med. 2022 Apr;63(4):528-535
pubmed: 34385343
Mol Imaging. 2014;13(5):
pubmed: 24825298
Ann Oncol. 2007 Jun;18(6):977-84
pubmed: 17229773
J Immunother. 2016 Jul-Aug;39(6):223-32
pubmed: 27227324
Swiss Med Wkly. 2017 Nov 29;147:w14545
pubmed: 29185244
PLoS One. 2011;6(10):e25791
pubmed: 21991353
Cell Mol Life Sci. 2013 Oct;70(20):3973-85
pubmed: 23728098
Methods Enzymol. 2012;503:255-68
pubmed: 22230572
Nucl Med Biol. 2015 Feb;42(2):78-84
pubmed: 25459109
Annu Rev Chem Biomol Eng. 2011;2:281-98
pubmed: 22432620
Bioconjug Chem. 2016 Mar 16;27(3):716-26
pubmed: 26781756
Biomaterials. 2021 Jan;266:120381
pubmed: 33120197
Semin Cancer Biol. 2021 Jul;72:185-197
pubmed: 33465471
Cancers (Basel). 2020 Oct 16;12(10):
pubmed: 33081407
Cancers (Basel). 2020 Dec 30;13(1):
pubmed: 33396753
J Biol Chem. 2011 Feb 18;286(7):5234-41
pubmed: 21138843
Cancer Discov. 2021 Oct;11(10):2474-2487
pubmed: 33941592
J Immunother. 2009 Oct;32(8):817-25
pubmed: 19752752
Bioconjug Chem. 2017 May 17;28(5):1371-1381
pubmed: 28388844
NPJ Breast Cancer. 2020 Mar 12;6:10
pubmed: 32195333
Breast Cancer Res. 2014 Mar 05;16(2):209
pubmed: 24887180
J Control Release. 2019 Aug 10;307:379-392
pubmed: 31252038
Cancers (Basel). 2019 Aug 14;11(8):
pubmed: 31416167
Drug Resist Updat. 2015 Jan;18:36-46
pubmed: 25476546